单肺移植术后自体肺肺癌的临床病理特征与预后
回顾性分析中日友好医院2017年9月至2021年6月247例单肺移植受者中12例自体肺发生肺癌的临床、病理及随访资料,探讨其临床病理特征与预后。12例中11例有吸烟史,移植前原发疾病以特发性肺纤维化为主(8例),移植至肺癌确诊间隔30.0±16.2个月,组织学以鳞状细胞癌为主(7例),中位生存时间7个月,1年累积生存率9.2%。
要点
- 单肺移植后自体肺肺癌多见于有吸烟史、移植前特发性肺纤维化者。
- 组织学类型以鳞状细胞癌为主,多数确诊时已为Ⅳ期,预后极差。
- 对移植后高危人群密切监测、早期发现肿瘤可能延长生存时间。
核心结论
- 单肺移植后自体肺患肺癌的发病风险增加,预后极差。
- 组织学类型大多数为鳞状细胞癌,对移植后高危人群密切监测早期发现肿瘤可能会延长生存时间。
研究设计与样本
- 回顾性分析2017年9月至2021年6月中日友好医院247例单肺移植术受者中12例自体肺发生肺癌患者的临床、病理及随访资料。
- 12例中男11例、女1例,年龄46~67(59.25±5.75)岁。
主要发现
- 12例受者中11例移植前有吸烟史,移植前肺原发疾病包括特发性肺纤维化8例、结缔组织病相关性肺间质病3例和慢性阻塞性肺病1例。
- 移植到自体肺继发肺癌的时间间隔为3~53(30.0±16.2)个月,11例确诊肺癌时相关的肿瘤标志物升高。
- 胸部CT和(或)PET-CT显示自体肺新发结节或高FDG摄取结节。
- 12例肺癌组织学类型包括1例小细胞癌和11例非小细胞肺癌(7例鳞状细胞癌,3例腺癌和1例SMARCA4缺失型未分化癌)。
- 临床分期Ⅳ期8例、Ⅲ期1例、Ⅰ期3例;随访至2024年9月,10例死亡、1例生存、1例失访,中位生存时间7个月(2~47个月),1年累积生存率为9.2%。
关键数值与推荐
- 单肺移植到自体肺继发肺癌的时间间隔为3~53(30.0±16.2)个月。
- 中位生存时间7个月(2~47个月),1年累积生存率为9.2%。
临床怎么用
- 对单肺移植后高危人群(尤其有吸烟史、移植前特发性肺纤维化者)密切监测,以期早期发现自体肺肺癌。
- 3例Ⅰ期和1例Ⅲ期患者接受手术治疗,Ⅳ期患者采用放、化疗和姑息疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the clinicopathological characteristics and prognosis of lung cancer arising in the native lung after single lung transplantation for end-stage lung disease. Methods: We conducted a respective analysis of the clinical, pathological, and follow-up data of 12 recipients who developed lung cancer in the native lung after single-lung transplantation at China-Japan Friendship Hospital from September 2017 to June 2021, among a total of 247 single-lung transplantations performed during this period. Eleven were male and 1 was female, with ages ranging from 46-67 (59.25±5.75) years. Results: Of the 12 recipients, 11 had a smoking history before transplantation. The underlying diagnosis of lung diseases before transplantation included 8 cases of idiopathic pulmonary fibrosis, 3 cases of connective tissue disease-associated interstitial lung disease, and 1 case of chronic obstructive pulmonary disease. The time interval from transplantation to the development of lung cancer in the native lung was 3 to 53 months, with an average of (30.0±16.2) months. Eleven patients had elevated levels of serum tumor markers at the time of lung cancer diagnosis. CT/PET-CT showed new nodules or FDG avidity in the native lung. The histological types of lung cancer in the 12 cases included 1 case of small cell carcinoma and 11 cases of non-small cell lung cancer (7 cases of squamous cell carcinoma, 3 cases of adenocarcinoma, and 1 case of SMARCA4-deficient undifferentiated carcinoma). There were 8 cases in clinical stage Ⅳ, 1 case in stage Ⅲ, and 3 cases in stageⅠ. Three patients in stage Ⅰ and one patient in stage Ⅲ underwent surgical treatment, while patients in stage Ⅳ were treated with radiotherapy, chemotherapy, and palliative care. At the end of this study, 10 patients had died, 1 patient survived, and 1 patient was lost to follow-up. The median survival time was 7 months (ranging from 2 to 47 months), and the 1-year cumulative survival rate was 9.2%. Conclusions: The risk of developing lung cancer in the native lung after single lung transplantation is increased. The prognosis is very poor. Most of the histological types are squamous cell carcinoma. Close monitoring of high-risk populations after transplantation for early tumor detection may prolong survival time. 目的: 探讨终末期肺疾病患者单肺移植术后自体肺发生肺癌的临床病理特征及预后。 方法: 回顾性分析2017年9月至2021年6月中日友好医院247例单肺移植术受者中12例自体肺发生肺癌患者的临床、病理及随访资料,其中男11例,女1例,年龄46~67(59.25±5.75)岁。分析患者临床病理特征与预后的相关因素。 结果: 12例受者中11例移植前有吸烟史,移植前肺原发疾病包括特发性肺纤维化8例,结缔组织病相关性肺间质病3例和慢性阻塞性肺病1例,移植到自体肺继发肺癌的时间间隔为3~53(30.0±16.2)个月,11例确诊肺癌时相关的肿瘤标志物升高,胸部CT和(或)PET-CT显示自体肺新发结节或高FDG摄取结节。12例肺癌组织学类型包括1例小细胞癌和11例非小细胞肺癌(7例鳞状细胞癌,3例腺癌和1例SMARCA4缺失型未分化癌)。临床分期Ⅳ期8例,Ⅲ期1例,Ⅰ期3例;3例Ⅰ期和1例Ⅲ期患者接受手术治疗,Ⅳ期患者采用放、化疗和姑息疗法。随访至2024年9月,10例死亡,1例生存,1例失访,中位生存时间7个月(2~47个月),1年累积生存率为9.2%。 结论: 单肺移植后自体肺患肺癌的发病风险增加,预后极差,组织学类型大多数为鳞状细胞癌,对移植后高危人群密切监测早期发现肿瘤可能会延长生存时间。.
引用
- Liu HY, Cheng N, Guo LJ, et al. [Clinicopathological characteristics,prognosis and related factors of lung cancer arising in the native lung following single lung transplantation]. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40159054. doi:10.3760/cma.j.cn112147-20241203-00716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。